Welcome to our dedicated page for BIODESIX SEC filings (Ticker: BDSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want the quick path to Biodesix鈥檚 most revealing disclosures? Investors tracking blood-based diagnostic innovators like Biodesix (BDSX) often need to pinpoint reimbursement updates, R&D spend on new lung biomarkers, or insider stock moves before clinical data drops. This SEC filings hub answers those questions in one place.
Navigate straight to the document you need鈥攚hether it鈥檚 the BDSX quarterly earnings report 10-Q filing that details Nodify Lung revenue, the BDSX annual report 10-K simplified for risk factors around FDA laboratory-developed tests, or the BDSX proxy statement executive compensation that links pay to diagnostic pipeline milestones. Stock Titan鈥檚 AI reads every page, producing concise summaries so you can scan complex tables in seconds. That means BDSX SEC filings explained simply, without losing critical nuance.
AG真人官方-time alerts flag BDSX Form 4 insider transactions, letting you monitor executive stock activity the moment it hits EDGAR. Need context? Our platform connects each trade to material disclosures so you understand motive, not just movement. You鈥檒l also find:
- BDSX 8-K material events explained for coverage-decision news or new assay launches
- BDSX earnings report filing analysis that compares quarter-over-quarter margin shifts
- BDSX executive stock transactions Form 4 with historical trend charts
From understanding BDSX SEC documents with AI to drilling into BDSX insider trading Form 4 transactions in real time, this page keeps equity analysts, healthcare investors, and strategic partners informed鈥攚ithout wading through hundreds of pages.
Robin Harper Cowie, Biodesix (BDSX) officer reported the vesting of 3,157 restricted stock units (RSUs on 08/12/2025) representing rights to 3,157 shares, which increased the reporting persons beneficial ownership to 251,782 shares. The following day (08/13/2025) 988 shares were sold at a weighted average price of $0.4163 to cover taxes arising from the vesting, leaving 250,794 shares beneficially owned. The filing shows the reporting person holds 6,313 RSUs in total that vest in 16 quarterly installments beginning February 8, 2022 and have no expiration date.
This transaction is a routine equity compensation settlement and tax withholding sale rather than an open-market disposition for liquidity; the reporting person remains a significant shareholder and continues to hold vested shares and unvested RSUs.
Kieran O'Kane, Chief Commercial Officer of Biodesix, Inc. (BDSX), reported the vesting of restricted stock units and a small automatic sale to cover taxes. On 08/12/2025, 1,489 RSUs vested, each representing a contingent right to one share. Following vesting the filing shows 140,541 shares beneficially owned. On 08/13/2025, 476 shares were sold automatically to cover taxes at a weighted-average price of $0.4163, leaving the Reporting Person with 140,065 shares. The filing also reports 2,979 RSUs remaining outstanding that vest quarterly beginning February 8, 2022, subject to continued service, and these RSUs have no expiration date.
Biodesix, Inc. (BDSX) reporting person Gary Anthony Pestano, Chief Development Officer, had restricted stock units (RSUs) vest on 08/12/2025 that converted into 1,379 shares of common stock. The filing shows those 1,379 shares were recorded as acquired on 08/12/2025 and, to satisfy tax withholding, 442 shares were sold on 08/13/2025 at a weighted average price of $0.4163 per share (individual sale prices ranged from $0.4076 to $0.43). After these transactions, Mr. Pestano beneficially owned 157,878 shares of common stock. The RSUs vest quarterly in 16 installments beginning February 8, 2022, have no expiration date, and the sold shares were transacted automatically by the issuer's broker to cover taxes.
Chris Vazquez, Chief Accounting Officer of Biodesix, Inc. (BDSX), reported equity changes tied to vesting of restricted stock units (RSUs). On 08/12/2025 the reporting person was issued 602 RSUs, each representing a contingent right to one share of common stock; after vesting and automatic sales to cover taxes, the reporting person beneficially owned 18,603 shares. On 08/13/2025 the filing shows an automatic sale of 228 shares at a weighted average price of $0.4163 (sales occurred within a $0.4076鈥�$0.43 range) resulting in 18,375 shares beneficially owned following the transactions. The RSUs vest in 16 successive quarterly installments beginning February 8, 2022, are generally conditioned on continued service, and have no expiration date.
FAQ
What is the current stock price of BIODESIX (BDSX)?
What is the market cap of BIODESIX (BDSX)?
